Latest Pharma and Biotech News
Biotechnology
28 November 2024 Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma.
Today's issue
Refine Search
Biotechnology
AstraZeneca and Daiichi Sankyo’s breast cancer med Enhertu (trastuzumab deruxtecan) will be included in China’s state-run health insurance scheme from next year, boosting availability at the cost of reduced pricing. 29 November 2024
Biotechnology
Minghui Pharmaceutical has reported encouraging results from a Phase III trial of MH004 (tofacitinib etocomil) in mild to moderate atopic dermatitis (AD). 29 November 2024
Biotechnology
Allink Biotherapeutics, a Chinese start-up focused on bispecific antibody and antibody-drug conjugates (ADC), has raised $42 million in a financing round led by Lanchi Ventures. 29 November 2024
Biotechnology
China’s Innovent Biologics has announced that the updated 2024 National Reimbursement Drug List (NRDL) now includes Sintbilo (tafolecimab) injection, an anti-PCSK9 monoclonal antibody for the first time. The updated NRDL will be officially effective from January 1, 2025. 29 November 2024
Biotechnology
Zug-based Galderma has published positive results from the Phase III OLYMPIA 1 trial in JAMA Dermatology, as the company’s newly-minted shares change hands in record volumes. 29 November 2024
Biotechnology
Indian drugmaker Dr Reddy’s Laboratories has launched its toripalimab in the domestic market, sending the firm’s share up 2%. Toripalimab is a New Biological Entity (NBE), the company noted. 29 November 2024
Biotechnology
French pharma major Sanofi has added a new plant in Singapore to make vaccines and other medicines, as the company seeks to bolster preparedness for emergencies, including potential pandemics, according to Bloomberg and other media reports. 29 November 2024
Biotechnology
During the Belgian Economic Mission to Brazil, a historic Memorandum of Understanding (MoU) was signed between the Brazilian Oswaldo Cruz Foundation (Fiocruz) through its Institute of Technology on Immunobiologicals (Bio-Manguinhos), and the Belgian companies Quantoom Biosciences and Univercells. 29 November 2024
Biotechnology
PTC Therapeutics is to sell its rare pediatric disease priority review voucher (PRV) for $150 million. 28 November 2024
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Biotechnology
Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of biological medicines from its R&D pipeline. 28 November 2024
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
All news
Biotechnology
Privately-held Canadian biotech AbCellera has announced a newly-minted deal with US biotech major Gilead Sciences. 14 June 2019
Biotechnology
Hutchison China MediTech, also known as Chi-Med, today announced that the independent Data Monitoring Committee (IDMC) of the Phase III pivotal study of surufatinib in advanced neuroendocrine tumors – extra-pancreatic (SANET-ep) has completed a planned interim analysis. 14 June 2019
Biotechnology
US pharma major Eli Lilly presented results at EULAR on Friday from the Phase IIIb/IV SPIRIT trial comparing its drug Taltz (ixekizumab) with AbbVie’s Humira (adalimumab) in active psoriatic arthritis (PsA). 13 June 2019
Biotechnology
Convincing physicians that their drug is a better option than AbbVie’s Humira has been an aim of a lot of companies at the EULAR congress again this year – with the Chicago-based drugmaker among them. 13 June 2019
Biotechnology
UK pharma major GlaxoSmithKline has teamed up with the University of California to establish a state-of-the-art laboratory for CRISPR technologies, the Laboratory for Genomics Research (LGR), in a five-year collaboration. 13 June 2019
Biotechnology
London and New York-listed Mereo BioPharma will regain rights to etigilimab from Celgene, as the American firm elected not to exercise an option on the candidate. 13 June 2019
Biotechnology
Privately-held Akrevia Therapeutics today announced that Joseph Farmer has been appointed as chief operating officer of the biopharma company launched by Atlas Ventures and F-Prime last September. 13 June 2019
Biotechnology
Shares in CymaBay Therapeutics fell by about 50% on Tuesday, after 12-week top-line results showed the firm’s nonalcoholic steatohepatitis (NASH) candidate seladelpar failed to outperform placebo. 13 June 2019
Biotechnology
Singapore-based Tessa Therapeutics, a Temasek-backed clinical stage biotech company, says it will establish a joint venture with China-Singapore Guangzhou Knowledge City (CSGKC). The joint venture will be the sole licensee of Tessa's cell therapies for research, clinical development and commercialization in China. 13 June 2019
Biotechnology
Novartis has boasted that Cosentyx (secukinumab) has become the first drug to show efficacy in all key manifestations of psoriatic arthritis (PsA). 12 June 2019
Biotechnology
Rare diseases specialist Swedish Orphan Biovitrum saw its shares gain nearly 3% to 175.50 kronor by mid-afternoon, after it revealed plans to take full control of a investigational compound that it had previously only licensed. 12 June 2019
Biotechnology
Oncologie, a company that is using proprietary biomarkers to drive development of new drugs for cancer, has closed an $80 Series B financing. 12 June 2019
Biotechnology
Swiss oncology-focused drug discovery firm ADC Therapeutics today announced that it has closed a $76 million expansion of its Series E financing, bringing the total gross proceeds raised in the Series E financing to $276 million. 12 June 2019
Biotechnology
Texas-based regenerative medicine and cell therapy company InGeneron has raised a further $23 million to advance a pivotal program in rotator cuff tendinopathy, a degenerative and often chronic condition found in a person’s shoulder. 12 June 2019
Biotechnology
Denmark’s Novo Nordisk has presented new safety data from the PIONEER 6 trial, testing its landmark oral formulation of the biologic semaglutide, compared with placebo, both in addition to standard of care. 12 June 2019
Biotechnology
US drugmaker AbbVie’s hopes that Skyrizi (risankizumab) will help to replace revenues lost when Humira (adalimumab) competition starts to bite, have been boosted further. 11 June 2019
Biotechnology
Tecentriq (atezolizumab) has been added to the UK’s Early Access to Medicines Scheme (EAMS) for use in combination with the chemotherapy agents carboplatin and etoposide, for the first-line treatment of adults with extensive-stage small cell lung cancer (SCLC). 11 June 2019
Biotechnology
The US Food and Drug Administration has approved top-selling immuno-oncology drug Keytruda (pembrolizumab), under priority review, for the first-line treatment of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC). 11 June 2019
Biotechnology
Hopes for Novavax’s once highly-anticipated respiratory syncytial virus (RSV) shot, ResVax, were dealt a new blow on Monday, as the US regulator said an additional Phase III trial would be needed. 11 June 2019
Biotechnology
A new biotech has been launched by GT Healthcare Capital Partners, a life science-focused private equity partnership specializing in capital investments and market scalability in the China region. 11 June 2019
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze